Skip to main content
SpringerLink
Log in

Stellenwert der BRAF-Inhibition bei der Haarzellleukämie

Role of BRAF inhibitors in hairy cell leukemia

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Hintergrund

Die Haarzellleukämie gehört zu den leukämischen, indolenten B‑Zell-Lymphomen.

Material und Methoden

Diese Arbeit basiert auf einer selektiven Literaturrecherche in der Datenbank PubMed zum Thema Haarzellleukämie und molekulare Marker sowie zielgerichtete Therapie.

Ergebnisse

Zahlreiche Erkenntnisse zu molekularen Ursachen haben in den letzten Jahren das Verständnis der Erkrankung beeinflusst und sie zu einem Paradebeispiel für Präzisionsonkologie gemacht. Mit der Entwicklung BRAF-gerichteter Therapie und der Entdeckung der BRAF-V600E-Mutation als wesentlichem Krankheitstreiber der Haarzellleukämie hat sich in kurzer Zeit ein effektives Behandlungsprinzip der Erkrankung entwickelt.

Schlussfolgerung

Der vorliegende Artikel erläutert die molekulargenetischen Hintergründe und Erkenntnisse sowie die Option der BRAF-Inhibition als wirksame therapeutische Option.

Abstract

Background

Hairy cell leukemia belongs to the group of indolent B‑cell lymphomas.

Materials and methods

This work is based on a selective literature search of hairy cell leukemia, molecular markers, and targeted therapy in the PubMed database.

Results

Many new insights in recent years regarding the molecular basis have changed the understanding of the disease Hairy cell leukemia has developed into a successful example of precision oncology. The development of BRAF-targeted treatments and the definition of BRAFV600E mutation as an essential driving mutation of the disease helped to further establish effective treatment.

Conclusion

The following review article will clarify the molecular background and findings, and the role of BRAF inhibition for hairy cell leukemia treatment, especially in the situation of refractory disease and relapse.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Schrek R, Donnelly WJ (1966) „Hairy“ cells in blood in lymphoreticular neoplastic disease and „flagelallated“ cells of normal lymph nodes. Blood 27(2):199–211

    Article  CAS  Google Scholar 

  2. Kreitman RJ, Arons E (2018) Update on hairy cell leukemia. Clin Adv Hematol Oncol 16(3):205–215

    PubMed  PubMed Central  Google Scholar 

  3. Tiacci E, Trifonov V, Schiavoni G, Holmes A, Kern W, Martelli MP, Pucciarini A, Bigerna B, Pacini R, Wells VA, Sportoletti P, Pettirossi V, Mannucci R, Elliott O, Liso A, Ambrosetti A, Pulsoni A, Forconi F, Trentin L, Semenzato G, Inghirami G, Capponi M, Di Raimondo F, Patti C, Arcaini L, Musto P, Pileri S, Haferlach C, Schnittger S, Pizzolo G, Foà R, Farinelli L, Haferlach T, Pasqualucci L, Rabadan R, Falini B (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364(24):2305–2315. https://doi.org/10.1056/NEJMoa1014209

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hüllein J, Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R, Hermann M, Herold M, Weichert W, Dearden C, Haferlach T, Seiffert M, Hallek M, von Kalle C, Ho AD, Gaehler A, Andrulis M, Steurer M, Zenz T (2016) BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood 127(23):2847–2855. https://doi.org/10.1182/blood-2015-11-680074

    Article  CAS  PubMed  Google Scholar 

  5. Foucar K, Falini B, Catovsky D, Stein H (2008) Hairy cell leukaemia. In: Swerdlow SH, Camp E, Harris NL et al (Hrsg) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, S 188–190

    Google Scholar 

  6. Chihara D, Arons E, Stetler-Stevenson M, Yuan C, Zhou H, Raffeld M, Xi L, Steinberg SM, Wisch L, Feurtado J, James-Echenique L, Braylan R, Calvo KR, Maric I, Dulau A, Kreitman RJ (2019) Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia. J Clin Oncol 37(15_suppl):7003

    Article  Google Scholar 

  7. Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, Zaja F, Devlin S, Pulsoni A, Chung YR, Cimminiello M, Kim E, Rossi D, Stone RM, Motta G, Saven A, Varettoni M, Altman JK, Anastasia A, Grever MR, Ambrosetti A, Rai KR, Fraticelli V, Lacouture ME, Carella AM, Levine RL, Leoni P, Rambaldi A, Falzetti F, Ascani S, Capponi M, Martelli MP, Park CY, Pileri SA, Rosen N, Foà R, Berger MF, Zinzani PL, Abdel-Wahab O, Falini B, Tallman MS (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747. https://doi.org/10.1182/blood-2015-11-680074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Falini B, Martelli MP, Tiacci E (2016) BRAF V600E mutation in hairy cell leukemia: from bench to bedside. Blood 128:15

    Article  Google Scholar 

  9. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ (1997) Differential regulation of Raf‑1, A‑raf, and B‑raf by oncogenic ras and tyrosine kinases. J Biol Chem 272(7):4378–4383

    Article  CAS  Google Scholar 

  10. Chong H, Lee J, Guan KL (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20(14):3716–3727

    Article  CAS  Google Scholar 

  11. Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T (2015) Recurrent CDKN1B (p27) mutations in hairy cell leukemia. Blood 126(8):1005–1008. https://doi.org/10.1182/blood-2015-04-643361

    Article  CAS  PubMed  Google Scholar 

  12. Durham BH, Getta B, Dietrich S, Taylor J, Won H, Bogenberger JM, Scott S, Kim E, Chung YR, Chung SS, Hüllein J, Walther T, Wang L, Lu SX, Oakes CC, Tibes R, Haferlach T, Taylor BS, Tallman MS, Berger MF, Park JH, Zenz T, Abdel-Wahab O (2017) Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations. Blood 130(14):1644–1648. https://doi.org/10.1182/blood-2017-01-765107

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Waterfall JJ, Arons E, Walker RL et al (2014) High prevalence of MAP2K1 mutations in variant and IGHV4-34 expressing hairy cell leukemias. Nat Genet 46(1):8–10

    Article  CAS  Google Scholar 

  14. Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, Hu W, Beguelin W, Monette S, Duy C, Rampal R, Telis L, Patel M, Kim MK, Huberman K, Bouvier N, Berger MF, Melnick AM, Rosen N, Tallman MS, Park CY, Abdel-Wahab O (2014) Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med 6(238):238ra71. https://doi.org/10.1126/scitranslmed.3008004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Akaraca AU, Shende VH, Ramsay AD et al (2013) BAFV600E mutation specific antibody, a sensitive diagnostic marker revealing minimal residual disease on hairy cell leukaemia. Br J Haematol 162(6):848–851

    Article  Google Scholar 

  16. Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B (2017) Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood 129(5):553–560. https://doi.org/10.1182/blood-2016-01-689422

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T (2012) BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med 366(21):2038–2040. https://doi.org/10.1056/NEJMc1202124

    Article  PubMed  Google Scholar 

  18. Dietrich S, Hüllein J, Hundemer M, Lehners N, Jethwa A, Capper D, Acker T, Garvalov BK, Andrulis M, Blume C, Schulte C, Mandel T, Meissner J, Fröhling S, von Kalle C, Glimm H, Ho AD, Zenz T (2013) Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia. J Clin Oncol 31(19):e300–e303. https://doi.org/10.1200/JCO.2012.45.9495

    Article  CAS  PubMed  Google Scholar 

  19. Follows GA, Sims H, Bloxham DM, Zenz T, Hopper MA, Liu H, Bench A, Wright P, Van’t Veer MB, Scott MA (2013) Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. Br J Haematol 161(1):150–153. https://doi.org/10.1111/bjh.12201

    Article  CAS  PubMed  Google Scholar 

  20. Peyrade F, Re D, Ginet C, Gastaud L, Allegra M, Ballotti R, Thyss A, Zenz T, Auberger P, Robert G (2013) Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. Haematologica 98(2):e20–e22. https://doi.org/10.3324/haematol.2012.082404

    Article  PubMed  PubMed Central  Google Scholar 

  21. Vergote V, Dierickx D, Janssens A, Verhoef G, Tousseyn T, Vandenberghe P, Wolter P, Delforge M (2014) Rapid and complete hematological response of refractory hairy cell leukemia to the BRAF inhibitor dabrafenib. Ann Hematol 93(12):2087–2089. https://doi.org/10.1007/s00277-014-2104-2

    Article  CAS  PubMed  Google Scholar 

  22. Pettirossi V, Santi A, Imperi E et al (2015) BRAF inhibitors reverse the unique signature in phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood 125(8):1207–1216

    Article  CAS  Google Scholar 

  23. Tiacci E, De Carolis L, Simonetti E, Zaja F, Capponi M, Ambrosetti A, Lucia E, Antolino A, Pulsoni A, Ferrari S, Zinzani P, Rigacci L, Gaidano G, Della Seta R, Frattarelli N, Falcucci P, Visani G, Foà R, Falini B (2019) The BRAF inhibitor, vemurafenib plus rituximab produces a high rate of deep and durable responses in relapsed/refractory hairy cell leukemia: updated results of a phase-2-trial. Hematol Oncol 37:110–111. https://doi.org/10.1002/hon.72_2629

    Article  Google Scholar 

  24. Estey EH, Kurzrock R, Kantarjian HM et al (1992) Treatment of hairy cell leukemia with 2‑chlorodeoxyadenosine (2-CdA). Blood 79:882–887

    Article  CAS  Google Scholar 

  25. Piro LD, Carrera CJ, Carson DA et al (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2‑chlorodeoxyadenosine. N Engl J Med 322:1117–1121

    Article  CAS  Google Scholar 

  26. Saven A, Burian C, Koziol JA, Piro LD (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood 92:1918–1926

    Article  CAS  Google Scholar 

  27. Zinzani PL, Tani M, Marchi E et al (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2‑chlorodeoxyadenosine. Haematologica 89:309–313

    CAS  PubMed  Google Scholar 

  28. Else M, Dearden CE, Catovsky D (2015) Long-term follow-up after purine analogue therapy in hairy cell leukemia. Best Pract Res Clin Haematol 28:217–229. https://doi.org/10.1016/j.beha.2015.09.004

    Article  PubMed  PubMed Central  Google Scholar 

  29. Hacioglu S, Bilen Y, Eser A et al (2015) Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy. Hematol Oncol 33:192–198. https://doi.org/10.1002/hon.2177

    Article  CAS  PubMed  Google Scholar 

  30. Catovsky D, Matutes E, Talavera JG et al (1994) Long term results with 2’deoxycoformycin in hairy cell leukemia. Leuk Lymphoma 14(Suppl 1):109–113

    PubMed  Google Scholar 

  31. Kreitman RJ, Tallmann MS, Robak T, Coutre S, Wyndham HW, Stetler-Stevenson M, FitzGerald DJ, Lechleider R, Pastan R (2012) Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 30(15):1822–1828

    Article  CAS  Google Scholar 

  32. Rafel M, Cervantes F, Beltrán JM, Zuazu F, Hernández Nieto L, Rayón C, García Talavera J, Montserrat E (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 88(2):352–357

    Article  CAS  Google Scholar 

  33. Tiacci E, Park JH, De Carolis L et al (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med 373(18):1733–1747

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Onkologie und Hämatologie, Universitätsspital Zürich, Rämistr. 100, 8091, Zürich, Schweiz

    Thorsten Zenz

Authors
  1. Wiebke Rösler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thorsten Zenz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thorsten Zenz.

Ethics declarations

Interessenkonflikt

T. Zenz hat Honorare von Roche, Abbvie, Janssen, Innate Pharma, Janssen, AstraZeneca und Takeda erhalten. W. Rösler gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rösler, W., Zenz, T. Stellenwert der BRAF-Inhibition bei der Haarzellleukämie. Onkologe 26, 721–726 (2020). https://doi.org/10.1007/s00761-020-00786-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-020-00786-7

Schlüsselwörter

Keywords

Search

Navigation